Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.

Investigational new drugs - 1 Oct 2011

Quintás-Cardama Alfonso, Manshouri Taghi, Estrov Zeev, Harris David, Zhang Ying, Gaikwad Amos, Kantarjian Hagop M, Verstovsek Srdan

Abstract excerpt

We herein report on the activity of the JAK2/JAK3 small molecule inhibitor atiprimod on mouse FDCP-EpoR cells carrying either wild-type (JAK2 (WT)) or mutant (JAK2 (V617F)) JAK2, human acute megakaryoblastic leukemia cells carrying JAK2 (V617F) (SET-2 cell line), and human acute megakaryocytic le...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colony-Forming Units Assay
Share to Erythroid Precursor Cells
Share to Janus Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Membrane Potential, Mitochondrial

Share to Poly(ADP-ribose) Polymerases

Share to Spiro Compounds

Share to STAT Transcription Factors

Share to X-Linked Inhibitor of Apoptosis Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 20372971
DOI: 10.1007/s10637-010-9429-z
PMCID: PMC4170651

Genes

JAK2
JAK3
SET
STAT3
XIAP

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20372971-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.PMID 20372971Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.Semantic proximity Read ↗

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.Semantic proximity Read ↗

Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.Semantic proximity Read ↗

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.Semantic proximity Read ↗

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.Semantic proximity Read ↗

Targeting myeloproliferative neoplasms with JAK inhibitors.Semantic proximity Read ↗

Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms.Semantic proximity Read ↗

Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.Semantic proximity Read ↗

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.Semantic proximity Read ↗

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.